Abeona Therapeutics (ABEO) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
18 Nov, 2026Portfolio strategy
ZEVASKYN, the first and only approved autologous cell-based gene therapy for RDEB wounds, remains the primary operating and commercial priority.
FAYUVI is approved; royalties and sales milestones from the Ultragenyx license are expected to begin in 2027.
Taysha expects FDA feedback on its planned Rett syndrome submission in H1 2027; Beacon’s AAV204 ophthalmology programs remain preclinical, with clinical entry expected soon.
ABO-801 was added as a late-stage, clinically differentiated asset with potential to contribute revenue within five years.
ZEVASKYN launch and demand
Eight qualified treatment centers (QTCs) are active; four have treated a first patient, and all four remaining centers are targeted to treat in H1 2027.
H1 2027 planning assumes roughly one patient per QTC per quarter, with some high-volume centers treating more; the stated goal is double-digit treatment cadence by midyear.
More than 100 eligible patients have been identified; 20%-25% are active in QTCs, with prior authorizations filed and interest in treatment.
Of 15 patients treated through Q3, nine came from center patient pools and six were referrals; referrals are expected to rise as outcomes mature.
Operational coordination, out-of-state Medicaid and prior authorization requirements remain barriers; ~40% of identified patients are in a state with a QTC, and sites are sharing best practices.
Manufacturing and unit economics
Two distinct manufacturing issues—low yield and out-of-spec pan-CK identity testing—each occurred once in roughly 17 runs; process and assay improvements are underway with FDA engagement.
A Type C meeting on pan-CK specifications is planned for Q1 2027; meaningful updates on both manufacturing issues are expected in H1 2027.
Capacity expansion is staged: two consecutive months with four patients could trigger expansion from six to eight slots per month; two consecutive months at six could trigger expansion to 10, with a four-to-six-month hiring lead time.
Gross margin is projected at ~85% at six patients per month and closer to 90% at full capacity of 10 per month.
Latest events from Abeona Therapeutics
- A 12.49 million-share resale shelf follows the ABO-801 acquisition and $30 million private placement.ABEO
Registration filing - ABO-801 adds a redesigned EoE Phase III program alongside ZEVASKYN’s expanding launch.ABEO
Stifel 2026 Healthcare Conference 2026 - Strong histologic results; exploratory DSQ mapping informs symptom endpoint strategy.ABEO
Clinical Development History presentation - ZEVASKYN’s $11.4M Q2 revenue anchors a broader cell- and gene-therapy pipeline.ABEO
Corporate presentation - ZEVASKYN revenue rose 18% QoQ as ABO-801 advanced toward Phase III.ABEO
Q3 2026 - ZEVASKYN launch accelerates with rising revenue, broad access, and a robust pipeline of gene therapies.ABEO
H.C. Wainwright 28th Annual Global Investment Conference - Durable gene therapy launch advances with expanding treatment centers and strong patient access.ABEO
Morgan Stanley 24th Annual Global Healthcare Conference - Steady ZEVASKYN rollout, robust coverage, and pipeline advances set stage for strong future growth.ABEO
12th Annual Cantor Fitzgerald Global Healthcare Conference - Q2 2026 ZEVASKYN revenue up 31% to $11.4M, NTAP status secured, net loss $20.2M, cash $146.8M.ABEO
Q2 2026